ONCOGENEX ANNOUNCES COMPLETION OF $12.8 MILLION VENTURE FINANCING

OncoGenex Technologies Inc., a clinical-stage biotechnology company developing targeted therapeutics for the treatment of cancer, announced the completion of a $12.8 million (U.S.) oversubscribed series B2 round of private equity financing with participation from several leading venture capital firms. Existing investors participating in the round include Ventures West, H.I.G. Ventures, the Working Opportunity Fund managed by GrowthWorks Capital, and Business Development Bank of Canada. New investors include WHI Morula Fund, LLC, managed by William Harris Investors, and BC Advantage Funds.

Canada NewsWire Group (http://www.newswire.ca/en/releases/archive/August2005/16/c0469.html)